(Q53093977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

title

Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

M Petrillo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

G Amadio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

V Salutari

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

M G Di Stefano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

G Ferandina

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

G Scambia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

A Fagotti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

English

0 references

publication date

26 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Gynecologic Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

231-236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

A phase 3 trial of bevacizumab in ovarian cancer

2 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

Prediction of anti-angiogenesis escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.05.017

10.1016/J.YGYNO.2016.05.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27215633%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference